Eric Lefkofsky Sells 166,250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $74.10, for a total value of $12,319,125.00. Following the completion of the sale, the chief executive officer owned 9,008,033 shares in the company, valued at approximately $667,495,245.30. This represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Trading Up 0.5%

Shares of TEM stock opened at $77.21 on Thursday. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The firm has a market capitalization of $13.74 billion, a PE ratio of -64.88 and a beta of 4.86. The stock has a fifty day moving average of $83.06 and a two-hundred day moving average of $72.44. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. During the same period last year, the company earned ($0.46) earnings per share. The company’s quarterly revenue was up 84.7% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. As a group, research analysts expect that Tempus AI, Inc. will post -6.15 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC bought a new position in shares of Tempus AI in the third quarter valued at $25,000. Concord Wealth Partners grew its holdings in shares of Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after acquiring an additional 308 shares during the last quarter. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI during the third quarter worth $26,000. GAMMA Investing LLC purchased a new stake in shares of Tempus AI during the third quarter valued at $28,000. Finally, Allworth Financial LP lifted its holdings in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on TEM. BTIG Research boosted their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright dropped their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Morgan Stanley increased their price target on Tempus AI from $68.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Finally, Cowen downgraded Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $80.75.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.